Venture firm's SPAC Vickers Vantage II
Venture firm's SPAC Vickers Vantage II
Venture firm's SPAC Vickers Vantage II files for a $180 million IPO
Vickers Vantage II, the second blank check company formed by Singapore-based Vickers Venture Partners, filed on Thursday with the SEC to raise up to $180 million in an initial public offering.
The New York, NY-based company plans to raise $180 million by offering 18 million units at $10. Each unit consists of one share of common stock and one right to receive one-tenth of a share upon the completion of an initial business combination. The trust will be initially overfunded at $10.03 per unit.
Vickers Vantage II is led by CEO and Chairman Jeffrey Chi, who co-founded Vickers Vantage Partners and currently serves as a member of its investment committee.
The firm's previous SPAC, Vickers Vantage I, completed its combination with pain management biotech Scilex Holding (Nasdaq: SCLX; -97% from $10 offer price) in 2022.
Vickers Vantage II was founded in 2021 and plans to list on the Nasdaq under the symbol VCKBU. Cohen & Company Securities is the sole bookrunner on the deal.
Vickers Vantage II, the second blank check company formed by Singapore-based Vickers Venture Partners, filed on Thursday with the SEC to raise up to $180 million in an initial public offering.
The New York, NY-based company plans to raise $180 million by offering 18 million units at $10. Each unit consists of one share of common stock and one right to receive one-tenth of a share upon the completion of an initial business combination. The trust will be initially overfunded at $10.03 per unit.
Vickers Vantage II is led by CEO and Chairman Jeffrey Chi, who co-founded Vickers Vantage Partners and currently serves as a member of its investment committee.
The firm's previous SPAC, Vickers Vantage I, completed its combination with pain management biotech Scilex Holding (Nasdaq: SCLX; -97% from $10 offer price) in 2022.
Vickers Vantage II was founded in 2021 and plans to list on the Nasdaq under the symbol VCKBU. Cohen & Company Securities is the sole bookrunner on the deal.